Related Experiment Video
Updated: Jul 6, 2025
A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts
Published on: September 20, 2018
Juvenile idiopathic recurrent parotitis (JIRP) treated with short course steroids, a case series study and one decade
Farhad Salehzadeh1, Rasol Molatefi2, Ali Mardi3
1Pediatric Rheumatology, Pediatric Department, Bouali Children's Hospital, Ardabil University of Medical Sciences (ARUMS), Ardabil, Iran.
Insights
Juvenile idiopathic recurrent parotitis (JIRP) in children responds dramatically to short-course prednisolone treatment. This effective, fast, and inexpensive therapy offers a new management option for JIRP episodes.
Area of Science:
- Pediatric Otolaryngology
- Pediatric Rheumatology
- Pediatric Infectious Diseases
Background:
- Juvenile idiopathic recurrent parotitis (JIRP) presents as recurrent parotid gland inflammation in children.
- Current diagnostic and management guidelines for JIRP are lacking.
- This study evaluates a case series of JIRP patients with long-term follow-up.
Discussion:
- The study highlights the significant efficacy of short-course prednisolone in managing JIRP episodes.
- Early intervention with prednisolone on the first day of an episode demonstrated rapid symptom improvement.
- No new autoimmune disorders were observed during the decade-long follow-up period.
Key Insights:
- Short-course prednisolone is a highly effective treatment for juvenile idiopathic recurrent parotitis.
- The treatment shows a rapid and dramatic response, improving patient outcomes.
- Prednisolone offers a safe and cost-effective therapeutic approach for JIRP.
Outlook:
- Further research can explore optimal prednisolone dosing and treatment duration for JIRP.
- Investigating the long-term safety profile of repeated short-course prednisolone treatments is warranted.
- This approach may become a standard of care for JIRP management.
Background:
Juvenile idiopathic recurrent parotitis (JIRP) in children is a condition characterized with recurrent episodes of idiopathic parotid gland inflammation. Since there are no definitive guidelines for diagnosis and management of this condition, we present a consecutive case series of patients with more than one decade follow up and their dramatic response to short course treatment by prednisolone.
Methods:
We conducted this study by retrospectively reviewed medical charts of children who were diagnosed with JIRP, from 1 January 2002 to 29 February 2023. We performed usual serological tests to exclude some possible background. We administered short course prednisolone on first day of episode as divided dosage (0.5 mg /kg).
Results:
In this case series of 10 patients (70%) were male, median age of onset was 5 years, duration of episodes 5 days, and the mean course of disease were 3.8 years. The average follows up of patients was near 10 years. In comparison with their natural course of disease all patients showed a dramatic response to treatment on the first day of administration of prednisolone (P Value 0.005). For ten years follow up there was not any additional accompanying autoimmune disorder.
Conclusion:
Short course prednisolone on first day of each episode and its dramatic and meaningful response in our patients, introduce a new, effective, fast, and inexpensive regimen of therapy in patients with JIRP.
